236 related articles for article (PubMed ID: 15190518)
1. The leukemia controversy in myeloproliferative disorders: is it a natural progression of disease, a secondary sequela of therapy, or a combination of both?
Barbui T
Semin Hematol; 2004 Apr; 41(2 Suppl 3):15-7. PubMed ID: 15190518
[TBL] [Abstract][Full Text] [Related]
2. Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia.
Kiladjian JJ; Rain JD; Bernard JF; Briere J; Chomienne C; Fenaux P
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):417-21. PubMed ID: 16810617
[TBL] [Abstract][Full Text] [Related]
3. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
Nand S; Stock W; Godwin J; Fisher SG
Am J Hematol; 1996 May; 52(1):42-6. PubMed ID: 8638610
[TBL] [Abstract][Full Text] [Related]
4. Diagnosis and treatment of polycythemia vera and possible future study designs of the PVSG.
Michiels JJ; Barbui T; Finazzi G; Fuchtman SM; Kutti J; Rain JD; Silver RT; Tefferi A; Thiele J
Leuk Lymphoma; 2000 Jan; 36(3-4):239-53. PubMed ID: 10674896
[TBL] [Abstract][Full Text] [Related]
5. Prediction of thrombotic and hemorrhagic events during polycythemia vera or essential thrombocythemia based on leukocyte burden.
Lim Y; Lee JO; Kim SH; Kim JW; Kim YJ; Lee KW; Lee JS; Bang SM
Thromb Res; 2015 May; 135(5):846-51. PubMed ID: 25743883
[TBL] [Abstract][Full Text] [Related]
6. Treatment strategies in essential thrombocythemia. A critical appraisal of various experiences in different centers.
Barbui T; Finazzi G; Dupuy E; Kiladjian JJ; Brière J
Leuk Lymphoma; 1996 Sep; 22 Suppl 1():149-60. PubMed ID: 8951786
[TBL] [Abstract][Full Text] [Related]
7. New drugs in essential thrombocythemia and polycythemia vera.
Tefferi A; Elliott MA; Solberg LA; Silverstein MN
Blood Rev; 1997 Mar; 11(1):1-7. PubMed ID: 9218101
[TBL] [Abstract][Full Text] [Related]
8. [Polycythemia vera: current status of therapy].
Lengfelder E; Hehlmann R
Dtsch Med Wochenschr; 2000 Oct; 125(41):1243-7. PubMed ID: 11076265
[No Abstract] [Full Text] [Related]
9. Primary thrombocythemia: new drugs for an evolving disease.
Balduini CL
Haematologica; 1992; 77(4):297-301. PubMed ID: 1427439
[No Abstract] [Full Text] [Related]
10. Indications for lowering platelet numbers in essential thrombocythemia.
Barbui T
Semin Hematol; 2003 Jan; 40(1 Suppl 1):22-5. PubMed ID: 12682878
[TBL] [Abstract][Full Text] [Related]
11. Management of patients with essential thrombocythemia: current concepts and perspectives.
Briere J; Guilmin F
Pathol Biol (Paris); 2001 Mar; 49(2):178-83. PubMed ID: 11317966
[TBL] [Abstract][Full Text] [Related]
12. Treatment paradigms in the management of myeloproliferative disorders.
Fruchtman SM
Semin Hematol; 2004 Apr; 41(2 Suppl 3):18-22. PubMed ID: 15190519
[TBL] [Abstract][Full Text] [Related]
13. Modern treatment strategies in polycythemia vera.
Gilbert HS
Semin Hematol; 2003 Jan; 40(1 Suppl 1):26-9. PubMed ID: 12682879
[TBL] [Abstract][Full Text] [Related]
14. Treatment of polycythaemia vera and essential thrombocythaemia.
Tefferi A; Silverstein MN
Baillieres Clin Haematol; 1998 Dec; 11(4):769-85. PubMed ID: 10640216
[TBL] [Abstract][Full Text] [Related]
15. Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea.
Alvarez-Larrán A; Martínez-Avilés L; Hernández-Boluda JC; Ferrer-Marín F; Antelo ML; Burgaleta C; Mata MI; Xicoy B; Martínez-Trillos A; Gómez-Casares MT; Durán MA; Marcote B; Ancochea A; Senín A; Angona A; Gómez M; Vicente V; Cervantes F; Bellosillo B; Besses C
Ann Hematol; 2014 Dec; 93(12):2037-43. PubMed ID: 24981691
[TBL] [Abstract][Full Text] [Related]
16. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia.
Harrison CN; Campbell PJ; Buck G; Wheatley K; East CL; Bareford D; Wilkins BS; van der Walt JD; Reilly JT; Grigg AP; Revell P; Woodcock BE; Green AR;
N Engl J Med; 2005 Jul; 353(1):33-45. PubMed ID: 16000354
[TBL] [Abstract][Full Text] [Related]
17. Therapy for polycythemia vera and essential thrombocythemia is driven by the cardiovascular risk.
Barbui T; Finazzi G
Semin Thromb Hemost; 2007 Jun; 33(4):321-9. PubMed ID: 17525889
[TBL] [Abstract][Full Text] [Related]
18. Anagrelide: analysis of long-term efficacy, safety and leukemogenic potential in myeloproliferative disorders.
Fruchtman SM; Petitt RM; Gilbert HS; Fiddler G; Lyne A;
Leuk Res; 2005 May; 29(5):481-91. PubMed ID: 15755500
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic options for essential thrombocythemia and polycythemia vera.
Solberg LA
Semin Oncol; 2002 Jun; 29(3 Suppl 10):10-5. PubMed ID: 12096352
[TBL] [Abstract][Full Text] [Related]
20. Leukemic transformation in myeloproliferative neoplasms: therapy-related or unrelated?
Björkholm M; Hultcrantz M; Derolf ÅR
Best Pract Res Clin Haematol; 2014 Jun; 27(2):141-53. PubMed ID: 25189725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
